Topics

The Lymphoid Tissue Pharmacology of Antiretroviral Drugs

2016-03-16 03:58:49 | BioPortfolio

Summary

Hypothesis:

Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in macaques will translate into an ARV regimen with increased LN and GALT concentrations and a faster decay and more potent suppression of HIV replication in LT in HIV-infected persons.

Objectives:

1. Determine lymph nodes (LN) and gut-associated lymphoid tissue (GALT) pharmacokinetics (PK) in HIV-infected persons on an antiretroviral drug (ARV) regimen.

2. Determine virological responses of antiretroviral therapy in plasma, peripheral blood mononuclear cells (PBMCs) and lymphoid tissue (LT).

Description

This is a single-center study of 18 ARV naïve, HIV infected persons to assess impact of an ARV regimen on lymph node (LN) and (GALT) virus reservoirs.

All participants will give informed consent. At baseline, plasma and PBMCs will be obtained and all subjects will have an incisional biopsy of an inguinal LN and pinch biopsy of ileum and rectum via colonoscopy. The selected LT-enhanced ARV regimen will be initiated. Participants will return to the clinic at weeks 2 and 4 and then monthly for safety evaluations, CD4 T cell counts, plasma HIV-RNA and ARV drug concentrations in plasma and PBMCs. An intensive PK study will be performed at week 2. At months 3 and 6, the inguinal LN biopsy and pinch biopsies of ileum and rectum will be repeated.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

HIV Infection

Intervention

Anti-HIV Agents

Status

Not yet recruiting

Source

University of Nebraska

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-03-16T03:58:49-0400

Clinical Trials [1506 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of Direct Acting Anti-Viral Medications for Chronic HCV Infection

To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therap...

Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease

Understanding of how best to treat inflammatory bowel disease (IBD) has evolved over the last ten years. Evidence now suggests that the most effective therapy early in the course of Crohn'...

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period t...

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two a...

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be f...

PubMed Articles [14698 Associated PubMed Articles listed on BioPortfolio]

Design, Synthesis, Docking Studies and Biological Activities Novel 2,3-Diaryl-4-Quinazolinone Derivatives as Anti-HIV-1 Agents.

Although major efforts devoted to the efficient treatment of HIV-1 infection, it has remained one of the leading causes of deaths around the world. So development of anti-HIV-1 agents featuring novel ...

Molecular modelling, Synthesis and Evaluation of Flavone and Flavanone Scaffolds as Anti-inflammatory Agents.

The objective of the study was to develop new Cyclooxygenase-2 inhibitors as anti-inflammatory agents from synthetic route.

Assessment of latent infections in patients receiving biological therapies.

The use of biological (or targeted) therapies constitutes a major advance in the management of autoinflammatory and malignant diseases. However, due to the selective effect of these agents on the host...

Threshold value of the anti-HCV test in the diagnosis of HCV infection.

In the diagnosis of hepatitis C virus (HCV) infection, the first step is screening for anti-HCV antibodies, and positive results are generally confirmed with nucleic acid amplification tests. Recent s...

Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients.

: Pediatric patients treated for acute myeloid leukemia (AML) are at high risk of developing severe infectious complications. The choice of an optimum supportive treatment should be based on local epi...

Medical and Biotech [MESH] Definitions

Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

A species of Propionibacterium that occurs in raw milk and cheese. It produces ANTI-INFECTIVE AGENTS and ANTI-INFLAMMATORY AGENTS and is used as a PROBIOTIC.

A species of Bifidobacterium that occurs in the GASTROINTESTINAL TRACT of mammals and healthy humans from birth until late adulthood. It produces ANTI-VIRAL AGENTS and ANTI-INFLAMMATORY AGENTS and is used as a PROBIOTIC.

More From BioPortfolio on "The Lymphoid Tissue Pharmacology of Antiretroviral Drugs"

Quick Search

Relevant Topics

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...


Searches Linking to this Trial